key: cord-0780536-bsbe12cc
authors: Higdon, Melissa M; Wahl, Brian; Jones, Carli B; Rosen, Joseph G; Truelove, Shaun A; Baidya, Anurima; Nande, Anjalika A; ShamaeiZadeh, Parisa A; Walter, Karoline K; Feikin, Daniel R; Patel, Minal K; Deloria Knoll, Maria; Hill, Alison L
title: A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
date: 2022-04-18
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac138
sha: 24d45a8cf69031d67cbe9822842cda81ba9c92a2
doc_id: 780536
cord_uid: bsbe12cc

Billions of doses of COVID-19 vaccines have been administered globally, dramatically reducing SARS-CoV-2 incidence and severity in some settings. Many studies suggest vaccines provide a high degree of protection against infection and disease, but precise estimates vary and studies differ in design, outcomes measured, dosing regime, location, and circulating virus strains. Here we conduct a systematic review of COVID-19 vaccines through February 2022. We included efficacy data from Phase 3 clinical trials for 15 vaccines undergoing WHO Emergency Use Listing evaluation and real-world effectiveness for 8 vaccines with observational studies meeting inclusion criteria. Vaccine metrics collected include protection against asymptomatic infection, any infection, symptomatic COVID-19, and severe outcomes including hospitalization and death, for partial or complete vaccination, and against variants of concern Alpha, Beta, Gamma, Delta, and Omicron. We additionally review the epidemiological principles behind the design and interpretation of vaccine efficacy and effectiveness studies, including important sources of heterogeneity.

SARS-CoV-2's rapid global spread and alarming clinical severity have accelerated demand for vaccines that safely and effectively prevent disease or reduce severity. To date, 30 COVID-19 vaccines have received emergency use authorization in at least one country, and nearly 5 billion people have been vaccinated 1, 2 .

Evidence from clinical trials and observational studies overwhelmingly supports the safety and efficacy/effectiveness of numerous COVID-19 vaccines, especially against severe disease and death in fully-vaccinated individuals. However, precise estimates of vaccine efficacy and effectiveness have varied across studies due to a variety of factors. For example, efficacy against symptomatic COVID-19 for AstraZeneca's two-dose viral vector vaccine (AZD1222) ranged from 62-90% in Phase 3 clinical trials 3 , attributed to differences in dosing schedules. Observational studies in a variety of settings also produced a wide range of effectiveness estimates (50-100%) against different clinical outcomes 4-14 . The emergence of SARS-CoV-2 "variants of concern", including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) further confounds interpretation of estimates obtained from comparably-designed vaccine studies. Some variants are associated with higher viral load 15-19 , evasion of neutralizing antibodies ex vivo 20-25 , and lower vaccine effectiveness 13,19,26-29 . However, separating diminished protection against a variant from the effects of waning immunity, study methodology, or other contextual factors (e.g., lower use of nonpharmaceutical interventions) is complicated by their co-occurrence and endogeneity.

Previous reviews of COVID-19 vaccines have focused mainly on the developmental pathway and early results from pre-clinical and clinical trials, the immunological basis of vaccine-induced protection, a narrow subset of vaccines or clinical outcomes, or have been rapid in nature and limited to earlier studies [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . There remains an urgent need for comprehensive, up-to-date review of COVID-19 vaccine effects, including real-world evidence. Here, we systematically reviewed COVID-19 vaccine efficacy and effectiveness data against multiple clinical outcomes, for both full and partial immunization courses, by circulating SARS-CoV-2 variants of concern. We focused on studies conducted in primarily adult populations, for the primary vaccine course only (i.e., excluding "booster" doses), and outcomes measured within the first six months after the final vaccine dose.

We reviewed studies reporting vaccine efficacy (from randomized clinical trials) or effectiveness (from observational studies) 48,49 for vaccines which had received or submitted applications for Emergency Use Listing from WHO as of February 1, 2021 50 and had at minimum publicly-released data from completed Phase 3 trials ( Table 1) . We searched for clinical trial results published in peerreviewed scientific journals (via PubMed) and preprint servers (medRxiv, bioRxiv, SSRN), government public health, regulatory agency, and vaccine manufacturers' websites, and in news articles (Google). M a n u s c r i p t 5 Searches were conducted using the vaccine's brand, trade, or research name. For observational studies, we applied detailed queries to multiple databases (Supplementary Methods), and only included results that appeared in at least a detailed report/preprint. Study title and abstract were screened before progressing to full-text review ( Figure S1 ). We extracted vaccine efficacy/effectiveness against disease endpoints, specifically asymptomatic infection, any infection, symptomatic disease, severe disease (including "hospitalization"), and death (Table S1) .

Observational studies were only eligible if the comparison group included concurrent individuals (e.g., modeled or historic controls were excluded), outcomes were laboratory-confirmed, the study design attempted to account for confounding, vaccination status was determined by self-report for ⩽10% of participants, confidence intervals were reported, no significant bias was present as determined by expert opinion, controls were unvaccinated (e.g., excluded if "unvaccinated" included days 0-12 post-vaccination). Only studies comparing persons with and without the clinical outcome under investigation and with and without vaccination were included. Impact studies and studies evaluating progression to severe disease among SARS-CoV-2-positive individuals were excluded. For full immunization (1 or 2 doses, depending on the vaccine), results were included if at least 1 week had passed between the final dose and case detection; for partial immunization, cases must have occurred at least 2 weeks after dose 1 but before dose 2. We excluded efficacy/effectiveness values for which i) follow-up period after final dose was >6 months, ii) doses beyond the primary series were given (i.e., boosters), or iii) multiple vaccines were combined. We classified efficacy/effectiveness against specific SARS-CoV-2 variants if sequencing (or other molecular methods) either i) confirmed the variant in all cases contributing to the estimate or ii) confirmed the variant caused the vast majority of cases in sample of study participants or of the larger population from which they came. Our data are available on VIEW-hub, a weekly-updated resource developed by Johns Hopkins' International Vaccine Access Center (view-hub.org/resources) and in Table S1 .

Vaccine efficacy is evaluated in randomized controlled trials (RCTs) and is defined as the relative reduction in the probability of developing disease in a particular time period in vaccinated individuals compared to unvaccinated individuals. In RCTs, subjects are randomly assigned to receive the vaccine or not (instead usually receiving a placebo or another vaccine). Vaccine efficacy (VE) is calculated using the formula: , A c c e p t e d M a n u s c r i p t 6 where sometimes the denominator "# vaccinated" ("# unvaccinated") is replaced with the sum of the total time enrolled in the study among vaccinated (unvaccinated) subjects (i.e., the "person time") 51,52 . While RCTs are the gold-standard for vaccine studies 53 , they are costly and generally too small to evaluate rare outcomes (e.g., death).

Vaccine efficacy describes the relative, as opposed to absolute, risk of disease. This is a desired feature of a metric for vaccine strength, since absolute risk may change over time as the background disease incidence changes during an epidemic due to factors like seasonality and behavior change. For example, if the absolute risk of disease in one setting is reduced from 50% to 10% through vaccination, then the vaccine efficacy (80%) is the same as in another setting where the absolute risk was reduced from 5% to 1%. The value of vaccine efficacy also does not tell us whether vaccine failure occurs in a "leaky" or "all-or-nothing" way 52,54,55 .

Once a vaccine is shown to be safe and efficacious in clinical trials and is authorized for general use, further RCTs to evaluate efficacy under new conditions or in special populations are often considered unethical or impractical, especially in the setting of a wide-spread epidemic, because it necessitates withholding vaccines from people who might benefit from them. Instead, observational studies evaluating real-world effectiveness are used to augment efficacy trials, and include designs such as case-control studies (including test-negative designs) and cohort studies (prospective or retrospective) 52,56,57 . Although observational studies must carefully address biases due to differences in those who chose to or were eligible to receive vaccines compared to those who did not, they may provide a more realistic picture of population heterogeneity and include more high-risk groups compared to RCTs. During massive vaccination campaigns like those occurring for COVID-19, observational studies can have much larger sample sizes .

To measure vaccine efficacy/effectiveness, the specific clinical outcome that the vaccine is meant to prevent must be carefully defined. The ideal goal of vaccination is to completely prevent infection (and thus disease and transmission), meaning that vaccine-induced immunity blocks the earliest attempts of the pathogen to replicate within the body. This "sterilizing immunity" is rare, and vaccine efficacy/effectiveness against infection is difficult to measure 58,59 for short-lived and commonly asymptomatic infections like SARS-CoV-2 since it requires frequent testing of the study cohort. To reduce the public health impact of an infectious disease, prevention of severe disease (including hospitalization and death) is desired, even if infection still occurs 53,59,60 . But because most individuals with COVID-19 recover completely with only mild or moderate symptoms 61-63 , studies of severe outcomes can require hundreds of thousands of participants or months to years of observation time. For COVID-19, the primary endpoint for most clinical trials was symptomatic, laboratory-confirmed COVID-19 disease, 53 defined as the occurrence of COVID-19-associated symptoms (e.g., cough, shortness of breath, fever) in the presence of detectable SARS-CoV-2. This outcome choice represents a trade-off between public health importance and practicality. M a n u s c r i p t 7 Symptomatic disease is on the spectrum leading to severe disease but much more common, and testing can be restricted to those self-reporting symptoms. Although some trials reported efficacy against severe disease as secondary outcomes despite small numbers 64-76 , large observational studies provide more precise estimates.

COVID-19 vaccine studies were conducted by many independent research teams in diverse epidemic settings around the world ( Table 1, Table 2 , Table S1, Figure 1) . Consequently, there are several potential sources of heterogeneity between studies that make comparing vaccine efficacy/effectiveness estimates difficult 57,77 :

• Study population: Efficacy/effectiveness can be lower in studies including more participants at high risk of disease (e.g., comorbid individuals) or with reduced immune function (e.g., people living with HIV) . • Outcome and case definition: Vaccine efficacy/effectiveness differs between disease outcomes with varying severity. Even when studies have the same stated outcome, the case definition can vary substantially. For example, most clinical trials used 'symptomatic COVID-19 disease' as the primary outcome but included anywhere from 5 (for AstraZeneca/AZD1222 3 ) to 16 (Janssen/Ad26.COV2.S 66 ) different potential symptoms and varied in requiring one or two to be present. These differences are exacerbated in effectiveness studies that often rely on passive surveillance by health systems. In addition, different definitions in the timing of the disease outcome (e.g., death within 30 days after diagnosis) can lead to heterogeneities. • Follow-up period: Since developing an adaptive immune response after vaccination takes time 59,78-80 , studies that begin the follow-up period sooner could observe lower efficacy/effectiveness (e.g., 7+ days for Novavax/NVX-CoV2373 70 vs 28+ days for Janssen/Ad26.COV2.S 66 ). In addition, if immune protection wanes, studies with longer follow-up could have lower estimates. • Predominant variants: Some SARS-CoV-2 variants of concern have been observed to exhibit immune-escape properties 21,81 (e.g., Beta 28,82-84 , Delta 13,19,65 , Omicron 26,27,29 ). Studies conducted when such variants account for a large proportion of infections could have lower efficacy/effectiveness (Figure 1 ). • Study design and analysis: To make up for lack of randomization, vaccine effectiveness studies can attempt to reduce confounding through study design (e.g., the test-negative design) and during analyses (e.g., controlling for potential confounding variables in regression models). Some studies, especially those that use administrative data, may not collect and therefore cannot control for such possible confounders. Figure  2 , Figure S1 ). Vaccine efficacy against symptomatic COVID-19 was available for all 15 vaccines, ranging from 58-95%, with highest efficacy (>90%) from six products representing mRNA, protein subunit and viral vector platforms. Efficacy against any infection was available for five EUL authorized vaccines and against severe disease for six, though confidence intervals for severe disease tended to be wide due to limited sample sizes and trial durations (Figures 3-7 , Table S1 ).

We identified 107 real-world vaccine effectiveness studies meeting our inclusion criteria 4-14,19,26-29,38,84,93-179

. These studies covered eight vaccines: seven with WHO EUL authorization (all but Novavax's NVX-CoV2373) and one with EUL submission in progress (Gamaleya's Sputnik V)(Table 2, Figure S1 , Table S1 ). These observational studies provided metrics not reported in clinical trials for some vaccines, including effectiveness against severe outcomes, asymptomatic infection, any infection, specific circulating variants, and effectiveness of a single dose of two-dose vaccines (Figures 3-7) . In general, effectiveness estimates overlapped with efficacy estimates and were high for full vaccine courses. Vaccines were more effective at preventing severe infection or death compared to symptomatic COVID-19. The degree to which vaccines prevented any infection, and the degree to which partial courses prevented infection or disease, varied widely by product. Data were sparse for effectiveness against death or asymptomatic infection and the Gamma variant.

The other authorized two-dose mRNA vaccine, Moderna's mRNA-1273, was also relatively wellstudied, largely using data from the USA, Canada, and Qatar (Figure 4) . After dose 2, efficacy/effectiveness estimates in the general population (pre-Omicron) fell between 94-99% for death, 85-100% for severe disease, 87-100% for symptomatic disease, 83-100% for any infection, and 73-93% for asymptomatic infection. With only a single dose, values were 60-95% for severe disease, 60-95% for symptomatic disease, 65-95% for any infection, and 45-60% for asymptomatic infection. Studies in the UK, USA, and Denmark 27,29,136 estimated effectiveness against the Omicron variant after two doses was reduced to ~75% for symptomatic infection and to 30-40% for any infection. Some evidence for reduction in effectiveness against infection or severe disease with Beta after only 1 dose was observed in studies in Canada and Qatar 12,114 . Significant reductions were not consistently reported for effectiveness against other variants of concern.

AstraZeneca's two-dose viral vector vaccine (AZD1222) was also frequently studied, especially after only one dose, likely because the recommended interval between doses is longer than other vaccines (12 weeks) and some countries including the UK and Canada adopted the strategy of prioritizing first doses over second doses in early 2021 ( Figure 5 ). Efficacy/effectiveness against non-VOC strains, the Alpha variant (predominant during most studies), or mixes of strains after two doses was 85-100% for death or severe disease, 65-100% for symptomatic disease, 60-80% for any infection, and 22% for asymptomatic infection in the general population. After a single dose, efficacy/effectiveness was 80-96% for death, 75-92% for severe disease, 45-75% for symptomatic disease, and 35-95% for any infection. The Delta variant appeared to reduce effectiveness against symptomatic disease or infection compared to the earlier Alpha variant by 10-15% after 2 doses and M a n u s c r i p t 10 ~20-30% after a single dose in some 13,19,96,145,171 but not all 12,123 studies. Effectiveness against the Gamma variant was within the range of earlier strains. Clinical trial evidence from the South Africa site 82 suggested loss of efficacy against symptomatic infection with the Beta variant, but with much uncertainty (efficacy 10% CI [<0, 55]). No studies meeting our inclusion criteria reported on the protection that AZD1222 alone provided against the Omicron variant.

Janssen's Ad26.COV2.S single-dose viral vector vaccine was studied in a variety of settings around the world (Figure 6) , with efficacy/effectiveness estimates of 70-100% against death, 60-90% for severe disease, 50-80% for symptomatic disease, 50-80% for any infection, and 65% for asymptomatic infection. Protection against infection or severe outcomes appeared to be preserved with SARS-CoV-2 variants of concern, although confidence intervals were extremely wide and no data for Omicron were available meeting inclusion criteria.

Data were sparse for Gamaleya Institutes's two-dose viral vector vaccine Sputnik V (Figure 6) , despite its use in dozens of countries ( Table 1) . A single clinical trial estimated efficacy against symptomatic disease with non-VOC virus of 91% 72 , while an observational study in Hungary in the context of the Alpha variant reported effectiveness of 98% against death and 88% against any infection 178 . No studies measuring protection against the Beta, Delta, or Omicron variant met our inclusion criteria.

Estimates of vaccine efficacy and effectiveness were available for three different two-dose inactivated virus vaccines: CoronaVac (Sinovac), BBIBP-CorV (Sinopharm-Beijing), and BBV152 (Bharat) (Figure 7) . Effectiveness studies of Sinovac's inactivated virus vaccine CoronaVac were available from only six studies, despite being one of the most widely used vaccines worldwide. These complemented results from three separate clinical trials, including one restricted to health care workers. After two doses, in the general population, efficacy/effectiveness was 86% against death, 88-100% against severe disease, 65-85% against symptomatic disease, and 65-75% against any infection. With only one dose, these values were significantly reduced, to 46% for death, 37% for severe disease, and 16% for any infection. Lower values were reported in studies in older adults, including one study conducted in adults over 70 years old in Brazil during a time when Gamma was predominant 163 . The only other variant-specific study suggested effectiveness against any infection was preserved against the Delta variant 180 . Sinopharm-Beijing's BBIBP-CorV could only be assessed after both doses and using two observational studies 104,178 and a single clinical trial 89 . Efficacy/effectiveness 86% for death, 88% for severe disease, 78% for symptomatic disease, and 74% for any infection. The only information on variant-specific protection came from the study from Hungary, conducted during a time when the Alpha variant dominated, and suggested that protection against any infection was similar to non-VOC strains. Bharat's BBV152 was evaluated in only a single effectiveness study in health care workers 121 in addition to the initial Phase 3 trial 65 . Efficacy was 93% M a n u s c r i p t 11 for severe disease, 78% for symptomatic disease, 69% for any infection and 64% for asymptomatic infection. The RCT suggested that protection against symptomatic disease with the Delta variant was reduced by 10-15 percentage points, while the observational study suggested <50% effectiveness against Delta after 2 doses and none after only 1 dose.

Although at the time of writing there were at least 10 other COVID-19 vaccines that had received emergency authorization for widespread use in at least one country, we did not identify effectiveness studies meeting our inclusion criteria.

The development of COVID-19 vaccines has been an astounding feat of science. Within a year of detecting the first outbreak and isolating the SARS-CoV-2 virus, multiple vaccines were deployed around the world. In this review, we systematically collected efficacy and effectiveness values by vaccine platform, disease outcome, number of doses, and SARS-CoV-2 variant. These findings demonstrate robust evidence for the high efficacy of COVID-19 vaccines in clinical trials and high effectiveness in real-world settings. We found that across all vaccine platforms, protection against severe infection or death in the general population was at least 60% and most often close to 100%. Efficacy/effectiveness against symptomatic disease was heterogeneous between vaccine products and studies but was almost always greater than 50% and often greater than 90%. The vast majority of studies showed that vaccines provided protection against infection -not just diseasedemonstrating the potential for indirect protective effects ("herd immunity") via reduced transmission. The degree of protection offered by only a single dose of two-dose vaccine courses varied by product. Most vaccines retained high levels of protection for most SARS-CoV-2 variants, especially against severe outcomes. Some studies provided evidence of slight reductions in efficacy/effectiveness for infection or mild disease with the Beta and Delta strains for some vaccines. Although few studies of the Omicron variant were available at publication time, the available evidence supports larger reductions in protection against both mild and severe infection.

There are several important components of COVID-19 vaccine efficacy/effectiveness not addressed here. Vaccine-induced protection can wane over months or years 59,60,78,79,181 . While all estimates reviewed here were restricted to within 6 months of vaccination, waning is a critical issue to monitor for COVID-19 vaccines. A recent meta-analysis estimated efficacy/effectiveness drops ~10% for severe disease and ~20% for infection over five months 85 . These drops appear to be more extreme for the Omicron variant; but evidence suggests "booster" doses -administered in many countries during Fall/Winter 2021 -enhance immunogenicity and effectivenes 20,26,27,29,136,182,183 . However, the WHO stresses prioritization of primary doses globally 184 . M a n u s c r i p t 12 Unvaccinated individuals previously infected with SARS-CoV-2 have some protection against reinfection, estimated in recent study to be ~90% 185, 186 . Consequently, including previously-infected persons in the unvaccinated group of studies could bias estimates of effectiveness downward. Alternatively, if prior immunity synergizes with vaccine-induced immunity to enhance protection, this bias could be in the opposite direction. Of 107 observational studies included in this review, 33 are known to have included persons with previous SARS-CoV-2 infection. For studies that stratified efficacy/effectiveness estimates by prior infection status, results were mixed, finding higher, lower, or unchanged values in previously-infected individuals 107, 187 .

For multi-dose vaccine regimens, the time interval between doses may affect protection. Efficacy of AZD1222 (AstraZeneca) increased from 55% with <6 weeks between doses to 81% with >12 weeks 3 . In real-world settings, dose interval sometimes varied due to policies of delaying second doses in favor of universal partial vaccination 188, 189 , allowing for evaluation of its impact on neutralizing antibody levels and effectiveness 6, 19, 190 .

While most vaccine manufacturers and international advisory committees (including WHO 191 ) initially recommended all doses be with the same product, many countries allowed for "mixing and matching" of doses [192] [193] [194] . Effectiveness studies have shown that boosting AZD1222 with either mRNA vaccine increases neutralizing antibody levels compared to two doses of AZD1222 alone [195] [196] [197] [198] [199] , and is also more effective against preventing infection 153, 171, 200 . Further evaluation is needed to understand which COVID-19 vaccine combinations are safe and effective.

For an individual, the goal of vaccination against COVID-19 is to prevent disease, but from a population perspective, there is an additional goal to reduce transmission, which can eliminate the need for complete vaccine coverage. Some studies have observed a reduction in transmission in vaccinated individuals infected with SARS-CoV-2 201 by testing close contacts of cases 10, 123, 143, 149, 162, [202] [203] [204] . Others have reported reductions in viral load in the respiratory tract -expected to be a determinant of infectiousness -in vaccinated (versus unvaccinated) cases 19,166,176,205 .

Currently, approval of new COVID-19 vaccines typically requires Phase III trials directly measuring vaccine efficacy. However, as vaccine availability increases in the face of an ongoing epidemic, further placebo-controlled trials may be considered impractical or unethical. Instead, new vaccines or immunization schedules will likely be evaluated using "immunobridging": indirectly inferring vaccine efficacy by measuring immunological biomarkers (like neutralizing antibody levels) identified as correlates of protection 53,55, [206] [207] [208] . Such study designs -not reviewed here -have already been used for early assessment of waning rates 207, 209 , identifying potential loses in protection against new variants 24,25,210 , promoting the need for booster doses 24,25,211,212 , justifying heterologous vaccine courses 212,213 , expanding eligible age groups to children 214, 215 , and to grant initial emergency approval M a n u s c r i p t 13 to some vaccines (e.g. Medigen's MVC-COV1901 in Taiwan 216 ). As pre-approval efficacy trials become rarer, post-authorization vaccine effectiveness studies will become even more important.

While our review focused on studies conducted in adults, some countries have now expanded vaccination campaigns to include children as young as 2 years old 217, 218 . Limited studies suggest that comparable safety, immunogenicity, efficacy, and effectiveness to adults can be achieved with adjusted dosing [219] [220] [221] [222] . While children are at lower risk for severe disease, they are susceptible to infection, contribute to transmission, and -because they are more likely to have mild symptomsmay be less likely to be tested or reported as cases, and to isolate during infection. Thus, the ability of COVID-19 vaccines to prevent asymptomatic infection and reduce transmission is especially relevant to the population-level impact of pediatric vaccination.

In conclusion, data from a wide variety of study types and settings demonstrate that COVID-19 vaccines provide high levels of protection against severe disease, and additionally protect against infection and mild disease, even those caused by most SARS-CoV-2 variants of concern. Preliminary evidence supports the idea that the spread of the Omicron variant beginning late 2021 is at least partially driven by reductions in vaccine effectiveness. 

Compendium for bringing the study authors together to work on this paper.

MHH, AB, PS, KW, and MDK received funding to collect the data used in work through a contract from the Center for Epidemic Preparedness Innovations (CEPI) to the International Vaccine Access Center at Johns Hopkins University. CBJ and JGR received funding from the Novel Coronavirus Research Compendium at Johns Hopkins to conduct reviews of COVID-19 vaccine papers for other purposes. ALH and AAN received support from the US National Institutes of Health (NIH DP5OD019851). All other authors received no specific funding support for this work. The study sponsors had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. The views represented in this article do not necessarily reflect the views of the WHO or the NIH. For each country, the time period during which outcomes were observed during each vaccine trial is shaded grey. For each two week period, the average daily incidence of reported cases is shown (height of bars) 225 . The contribution of each major variant of concern to total case counts is estimated from the reported fraction of sequenced SARS-CoV-2 samples belonging to that strain (fill color) 226 . Figure includes only vaccine trials described in published or pre-print reports, trial sites with at least 10,000 individuals from the general adult population, and countries regularly reporting SARS-CoV-2 lineages to the GISAID database. a n u s c r i p t 33 is given by the labels on the left side ( "(reference number) Country, population"). Within each disease severity level, estimates are ordered alphabetically by country, and then by population. 

A global database of COVID-19 vaccinations

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers -a single centre cohort study

Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans -Five Veterans Affairs Medical Centers

Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection During a Delta Variant Epidemic Surge in Multnomah County

Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study

COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales

Effectiveness of the Ad26.Cov2.S Vaccine in Health Care Workers in South Africa

Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco

Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: a whole country retrospective view

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age populationfirst results from a cohort study in Southern Sweden

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study

Effectiveness of mRNA-1273 against delta, mu, and other of SARS-CoV-2: test negative case-control study

SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women

SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec

Effectiveness of COVID-19 Vaccines in Preventing Hospitalizations and Deaths in Colombia: A Pair-Matched, National-Wide Cohort Study in Older Adults

Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Effectiveness of Coronavirus Disease

Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study

Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants

Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study

BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of Coronavirus Disease 2019 Patients

North West London Covid-19 Vaccination Programme: Real-world evidence for Vaccine uptake and effectiveness: Retrospective Cohort Study

The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data

Waning Immunity after the BNT162b2 Vaccine in Israel

Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19

Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance -Nine States

Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

DIfferences in human immunodeficiency virus care and treatment among subpopulations in the united states

Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

Effectiveness of BNT162b2 and

COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a testnegative, case-control study

Time-Varying Effectiveness of Three COVID-19 Vaccines in Puerto Rico

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre study analysis by age-group, vaccine brand and time since vaccination, I-MOVE-COVID-19 and ECDC networks

Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study

Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation

Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England

COVID-19 impact and vaccine effectiveness among healthcare workers of a large University Hospital in Lombardy

Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany

Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers -a Danish cohort study

Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome 26

SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2

Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

Effectiveness of the CoronaVac Vaccine in Prevention of Symptomatic and Progression to Severe COVID-19 in Pregnant Women in Brazil

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS)

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

Effectiveness of the Single-Dose Ad26

Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland

Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national testnegative case-control study

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel

Estimating COVID-19 Vaccination Effectiveness Using Electronic Health Records of an

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel

Comparative Effectiveness of Moderna

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec

Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design

Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural

Molecular Screening

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Characteristics of Adult Outpatients and Inpatients with COVID-19 -11 Academic Medical Centers

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study

The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar

WHO. Interim statement on booster doses for COVID-19 vaccination

A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection

Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study

Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection

Delayed Second Dose Turns Into a Win for Vaccine-Starved Places

In Europe, more countries delay second vaccine doses or mull plans to do so

Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine

WHO. Interim statement on heterologous priming for COVID-19 vaccines

Mix-and-match COVID vaccines: the case is growing, but questions remain

Covid-19 global updates: Some countries defend mixing vaccines after WHO suggests booster strategy is 'chaotic

Why More People Are Getting Two Different Coronavirus Vaccines

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Heterologous ChAdOx1 nCoV-19 and mRNA-1273

Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study

Interpreting vaccine efficacy trial results for infection and transmission

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Effect of Vaccination on Transmission of SARS-CoV-2

Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Access Consortium. Access Consortium: Alignment with ICMRA consensus on immunobridging for authorising new COVID-19 vaccines

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Antibodies in Persons with Mild Covid-19

Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers

Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations: a modeling study

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of

Why Taiwan approved its own vaccine before phase III trials

Countries vaccinating children against COVID-19

Interim statement on COVID-19 vaccination for children and adolescents. World Health Organ

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19

Vaccine in Children 6 to 11 Years of Age

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

19-Vaccine-Demonstrates-90-Overall-Efficacy-and-100-Protection-Against-Moderate-and-Severe-Disease-in-PREVENT-19-Phase-3-Trial

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

An interactive web-based dashboard to track COVID-19 in real time

Global initiative on sharing all influenza data -from vision to reality

Efficacy and Safety of an Inactivated Whole-Virion Vaccine Against COVID-19, QazCovid-in®

A c c e p t e d M a n u s c r i p t